# COGNUTRIN in Breast Cancer Survivors

> **NCT01823991** · EARLY_PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 36 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** VitaBlue™
- **OTHER:** Placebo
- **DRUG:** Lovaza®

## Key facts

- **NCT ID:** NCT01823991
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-30
- **Primary completion:** 2017-04-05
- **Final completion:** 2018-05-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01823991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01823991, "COGNUTRIN in Breast Cancer Survivors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01823991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*